Medicare’s $50/month GLP-1 program starts July 1 — here’s exactly who can get it

Medicare has long been banned by federal law from covering medications prescribed solely for weight loss. Starting July 1, 2026, that effectively changes for the first time – not through an act of Congress, but through a workaround: a short-term demonstration program called the Medicare GLP-1 Bridge that lets eligible beneficiaries access certain weight-loss injections and pills for a flat $50 a month. A previous KFF analysis estimated that close to 14 million Medicare beneficiaries had a diagnosis of overweight or obesity in 2020, though applying the specific criteria that determine eligibility for the Bridge would reduce that number.

The reason this required a workaround at all comes down to how Medicare’s drug benefit is written. Under federal law, Medicare Part D plans cannot cover medications prescribed for weight loss, and drugs with FDA approval for both weight loss and other indications may only be covered by Part D plans for their non-weight-loss uses. Changing that restriction permanently would require Congress to pass new legislation. Instead, the Centers for Medicare and Medicaid Services used its authority to test coverage changes through demonstration programs.

The $50 monthly price looks straightforward on paper, but the mechanics behind it are more layered than most beneficiaries realize. The Bridge runs entirely outside the standard Part D benefit structure, operates through its own approval and payment system, and comes with a set of eligibility rules that will exclude some people who’d expect to qualify – including a category of GLP-1 users who are already on these drugs for other conditions.

What the Bridge Program Actually Is – and How GLP-1 Medicare Coverage Works

The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that provides eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. It operates outside the Medicare Part D benefit’s coverage and payment flow. As a result, Part D sponsors carry no financial risk for eligible GLP-1 drugs furnished under the Bridge, and they do not have to opt in for eligible beneficiaries to access these drugs.

Instead of going through each person’s individual drug plan, CMS uses a single central processor to manage prior authorization, claims adjudication, and pharmacy payment for the Bridge. CMS is utilizing Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Medicare GLP-1 Bridge. Humana handles prior authorizations, processes pharmacy claims, and pays pharmacies directly for drugs dispensed under the Bridge.

The program came together partly through deals President Trump announced with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs and lower GLP-1 costs on Medicare and Medicaid. According to CNBC’s reporting on those agreements, Medicare will start covering obesity drugs for some patients for the first time starting mid-2026. CMS originally announced two models to test expanded access to GLP-1 medications for people with Medicare: the GLP-1 Bridge and the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model. In May 2026, CMS announced that the Part D portion of the BALANCE Model will be delayed indefinitely and that the GLP-1 Bridge will be extended through December 31, 2027.

Which Drugs Are Covered

Beginning July 1, 2026, all formulations of Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound will be available to eligible beneficiaries through the Bridge. The single-dose vial and single-dose pen formulations of Zepbound are not covered under this program.

Foundayo (orforglipron) received FDA approval on April 1, 2026 – the second oral GLP-1 drug approved by the FDA for obesity, after the Wegovy pill from Novo Nordisk was approved in December 2025. Foundayo is a daily oral tablet, the first in this class to be taken as a pill rather than an injection. Oral Wegovy (semaglutide) tablets started the trend in December 2025, and Foundayo (orforglipron) tablets followed suit in April 2026. Wegovy is available under the Bridge in both weekly injectable and tablet forms. Zepbound (tirzepatide), manufactured by Eli Lilly, is included only as the KwikPen injectable.

Notably, Ozempic – the semaglutide injection widely prescribed for Type 2 diabetes – is not on the Bridge list. Drugs like Ozempic and Wegovy may be covered by regular Part D if prescribed for diabetes management or cardiovascular disease. The Bridge covers weight-loss indications only.

Who Qualifies – The BMI and Diagnosis Rules

Your Part D plan does not need to opt in to the program. If you meet the eligibility criteria, you can access the covered GLP-1 drugs regardless of which Part D plan you are enrolled in. But eligibility criteria are specific, and meeting one condition alone is not enough.

The BMI thresholds work in tiers. To qualify, beneficiaries must be enrolled in a standalone prescription drug plan or Medicare Advantage coordinated care plan that offers prescription drug coverage. Beyond plan enrollment, clinical eligibility breaks down by body weight and accompanying diagnosis:

A BMI of 35 or higher qualifies on its own. A BMI of 30 or higher qualifies when paired with a diagnosis of heart failure, uncontrolled hypertension, or chronic kidney disease. The lowest threshold is a BMI of 27 or higher – but that requires a diagnosis of pre-diabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease, according to CMS’s provider guidance.

GLP-1 hormones are released by the small intestine when food passes through the digestive system. These hormones trigger insulin release, block glucagon secretion, and slow stomach emptying – effects that lower blood sugar after eating. GLP-1 also affects brain areas that process hunger, prolonging feelings of fullness. The drugs approved under the Bridge mimic these effects pharmacologically, which is why the eligibility criteria focus on metabolic and cardiovascular conditions most closely linked to excess body weight.

CMS assesses clinical eligibility at the time GLP-1 therapy was first initiated, including for beneficiaries who started therapy before enrolling in Part D. If you’ve been on Wegovy for months through a private pay arrangement and then enroll in Medicare, your original initiation date is used for assessment – not your Medicare enrollment date.

Who Does Not Qualify (Despite Meeting BMI Criteria)

Several common conditions that GLP-1s are also prescribed for will actually make you ineligible for the Bridge – because people with those diagnoses access GLP-1s through their regular Part D plan instead.

The CMS beneficiary information page makes clear that Type 2 diabetes, obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) are indications already eligible for Part D coverage. Beneficiaries with those diagnoses are expected to use their Part D plan for GLP-1 access and therefore cannot use the Bridge.

The FDA approved Zepbound (tirzepatide) as the first and only prescription medication for adults with sleep apnea, and Wegovy received FDA approval for reducing the risk of cardiovascular death, heart attack, and stroke in patients with cardiovascular disease and obesity. If you’re already taking one of these medications for a qualifying condition such as Type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea, you’ll continue to get it through your regular Part D plan – the Bridge does not apply to you in that case.

How the $50 Copay Actually Works

Weight management medications including Wegovy, Zepbound, and Foundayo will be available to eligible Medicare beneficiaries with a $50 copay starting in July – a notable shift for Medicare, which has long been barred from covering weight-loss treatments.

The copay is flat and predictable. According to CMS’s beneficiary FAQ, the $50 monthly copayment stays consistent regardless of the Part D benefit phase – meaning it won’t shift based on whether you’ve reached your deductible or your out-of-pocket cap. Part D cost-sharing typically increases as a beneficiary moves through different phases of the benefit year, so the fixed rate is a real structural advantage.

The $50 copay does not apply to your Part D deductible, and it does not count toward the 2026 out-of-pocket maximum of $2,100 (which rises to $2,400 in 2027), per the same CMS guidance. If you have Extra Help (the low-income subsidy program that reduces drug costs for lower-income Medicare beneficiaries), those benefits will not reduce your Bridge copay either.

Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF, has been conducting research and analysis on Medicare policy issues since 2004 and leads work on Medicare prescription drug coverage. Speaking to KFF Health News, Cubanski put the cost in plain terms: “Fifty dollars a month sounds like a great deal compared to paying the discounted prices through TrumpRx and these other direct-to-consumer options, but it’s a lot of money for somebody who’s living on a $750-a-month Social Security check.”

The drug manufacturers participating in the program supply the medications at a fixed net price. According to senior administration officials, the two manufacturers agreed to sell their injectable GLP-1 products for a monthly starting price of $245 for people on Medicare and Medicaid. That’s a substantial reduction from current retail pricing: even with discounts, current cash prices typically range from $149 to $699 per month, according to NPR. About half of current GLP-1 users say these drugs were difficult for them to afford, according to KFF polling. A quarter described them as “very difficult” to afford.

How to Get Access – What Providers Need to Do

To access GLP-1 medications via the Bridge, an eligible beneficiary must have a medical provider submit a prior authorization request and a prescription for an eligible GLP-1 drug for a covered use. Prior authorization requests will be accepted electronically or by fax using the Medicare GLP-1 Bridge prior authorization form, and CMS strongly encourages providers to submit prior authorization electronically.

Providers do not need to be enrolled in Medicare to write the prescription or submit the prior authorization, but they must not appear on Medicare’s Preclusion List – the list of providers barred from participating in Medicare programs. Once the prior authorization is approved, beneficiaries can fill their prescription at a participating pharmacy. Pharmacies do not need to opt in to the program; they automatically participate.

Beneficiaries themselves don’t have to register or opt in for access. The administrative work falls on providers. If you believe you qualify, the clearest step is to schedule an appointment with your primary care doctor before July 1, confirm your BMI and diagnoses against the eligibility criteria, and ask your provider to initiate the prior authorization process through the Bridge’s central processor.

What Happens After December 2027

CMS will provide coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 through the Medicare GLP-1 Bridge – originally scheduled to end in December 2026, but now extended – and the administration has recently announced an indefinite delay in implementation of the BALANCE Model in Part D.

To continue accessing Medicare coverage of GLP-1s for obesity after the Bridge ends, beneficiaries would need to be enrolled in a Part D plan that participates in the longer-term BALANCE Model. CMS is aiming for robust Part D plan participation in the BALANCE model, but this remains uncertain. Transitioning from the mandatory Bridge to the voluntary BALANCE model sets up the possibility that some beneficiaries may need to switch Part D plans during open enrollment, with potential cost and coverage implications for other medications they use.

If the BALANCE Model remains delayed and the Bridge isn’t further extended, beneficiaries who start on a GLP-1 through this program could lose access to subsidized pricing in 2028.

What This Means for You

Check your BMI and your existing diagnoses against the three eligibility tiers. If your BMI is 35 or above with no qualifying conditions that would route you to Part D GLP-1 access, you’re likely in. If your BMI falls between 27 and 34, the qualifying conditions list – heart failure, uncontrolled hypertension, chronic kidney disease, pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease – determines whether you’re eligible. If you have Type 2 diabetes, sleep apnea, or MASH, those conditions route you to your regular Part D plan rather than the Bridge.

Clinicians are already bracing for one of the biggest drug rollouts in recent memory, with some expressing concern that the volume of new GLP-1 prescriptions could shortchange patient counseling on how to take the injectables and pills, adjust dosages, and manage side effects. Getting your prior authorization submitted early – as soon as July 1 – gives your provider more time and attention to work through the process rather than managing a queue of simultaneous requests.

The Bridge is nationwide and available in all states and territories, so geography isn’t a restricting factor. Your BMI, your diagnoses, your Part D enrollment status, and whether your provider can confirm your clinical eligibility going back to the date you first started GLP-1 therapy – not the date the Bridge launches – are what ultimately determine access.

Disclaimer: This information is not intended to be a substitute for professional financial advice, investment advice, tax advice, or legal advice, and is provided for informational purposes only. Always seek the guidance of a qualified financial advisor, accountant, or other licensed professional regarding your personal financial situation or investment decisions. Do not make financial, investment, or tax decisions based solely on information presented here. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of principal.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.

Read More: 7 Medicare Changes in 2026 Every Senior Needs to Know About